Switching stable patients with schizophrenia from depot and oral antipsychotics to long-acting injectable risperidone: Efficacy, quality of life and functional outcome

Human Psychopharmacology

Volumn 25, Issue 3, 2010, Pages 243-252

  Lloyd, Keith ^a   Latif, Muhammud A ^b   Simpson, Steve ^c   Shrestha, Keshar L ^d  

^a SWANSEA UNIVERSITY   (United Kingdom)

^b SUSSEX COMMUNITY NHS FOUNDATION TRUST   (United Kingdom)

^c Forston Clinic   (United Kingdom)

^d TYNE AND WEAR NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Efficacy; Functional outcome; Injection; Long acting; Quality of life; Risperidone

Indexed keywords

CARBAMAZEPINE; CHLORPROMAZINE; CLONAZEPAM; DIAZEPAM; GABAPENTIN; LEVOMEPROMAZINE; LITHIUM; LONG ACTING DRUG; LORAZEPAM; PHENYTOIN; PROCHLORPERAZINE; PROCYCLIDINE; PROMAZINE; RISPERIDONE; VALPROIC ACID; VENLAFAXINE; ZOPICLONE; DELAYED RELEASE FORMULATION; NEUROLEPTIC AGENT;

ADULT; ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT SATISFACTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUALITY OF LIFE; SCHIZOPHRENIA; SCORING SYSTEM; TREATMENT OUTCOME; ADMINISTRATION AND DOSAGE; ADOLESCENT; AGED; COMPARATIVE STUDY; CONVALESCENCE; DELAYED RELEASE FORMULATION; DIET THERAPY; DRUG EFFECTS; INTRAMUSCULAR DRUG ADMINISTRATION; MIDDLE AGED; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PATHOPHYSIOLOGY; PHYSIOLOGY; PSYCHOLOGY; TIME; VERY ELDERLY; YOUNG ADULT;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIPSYCHOTIC AGENTS; DELAYED-ACTION PREPARATIONS; FEMALE; HUMANS; INJECTIONS, INTRAMUSCULAR; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; QUALITY OF LIFE; RECOVERY OF FUNCTION; RISPERIDONE; SCHIZOPHRENIA; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77950915234     PISSN: 08856222     EISSN: 10991077     Source Type: Journal    
DOI: 10.1002/hup.1108     Document Type: Article

References (46)

1. American Psychiatric Association. 2000. Diagnostic and Statistical Manual of Mental Disorders, 4th edn, Text revised. American Psychiatric Association: Washington DC.
2. Awad AG, Hogan TP. 1994. Subjective response to neuroleptics and the quality of life: implications for treatment outcome. Acta Psychiatr Scand Suppl 380: 27-32.
3. Bagnall AM, Jones L, Ginnelly L, et al. 2003. A systematic review of atypical antipsychotic drugs in schizophrenia. Health Technol Assess 7: 1-193. (Pubitemid 36903285)
4. Barnes TR, Curson DA. 1994. Long-term depot antipsychotics: a risk benefit assessment. Drug Saf 10: 464-479.
5. Carman J, Peuskens J, Vangeneugden A. 1995. Risperidone in the treatment of negative symptoms of schizophrenia: a meta-analysis. Int Clin Psychopharmacol 10: 207-213.
6. Chue P, Eerdekens M, Augustyns I, et al. 2005. Comparative efficacy and safety of long-acting risperidone and risperidone oral tablets. Eur Neuropsychopharmacol 15: 111-117. (Pubitemid 39574406)
7. Csernansky JG, Mahmoud R, Brenner R. 2002. A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. New Engl J Med 346: 16-22. (Pubitemid 34438915)
8. Curson DA, Barnes TR, Bamber RW, Platt SD, Hirsch SR, Duffy JC. 1985. Long-term depot maintenance of chronic schizophrenic out-patients: the seven-year follow-up of the Medical Research Council fluphenazine/placebo trial, II: the incidence of compliance problems, side-effects, neurotic symptoms and depression. Br J Psychiatry 146: 469-474.
9. Davis JM, Chen N, Glick ID, 2003. A meta-analysis the of efficacy of second-generation antipsychotics. Arch Gen Psychiatry 60: 553-564.
10. Davis JM, Malaton L, Watanabe MD, Blake L, Malaton L. 1994. Depot at antipsychotic drugs: place in therapy. Drugs 47: 741-773. (Pubitemid 24151095)
11. De Graeve D, Smet A, Mehnert A, et al. 2005. Long-acting risperidone compared with oral olanzapine and haloperidol depot in schizophrenia: a Belgian cost-effectiveness analysis. Pharmacoeconomics 23(Suppl 1): 35-47.
12. Edwards NC, Rupnow MF, Pashos CL, Botteman MF, Diamond RJ. 2005. Cost-effectiveness model of long-acting risperidone in schizophrenia in the US. Pharmacoeconomics 23: 299-314. (Pubitemid 40663635)
13. Eerdekens M, Van Hove I, Remmerie B, Mannaert E. 2004. Pharmacokinetics and tolerability of long-acting risperidone in schizophrenia. Schizophrenia Res 70: 91-100. (Pubitemid 38916632)
14. Ereshefsky L, Mascarenas CA. 2003. Comparison of the effects of different routes of antipsychotic administration on pharmacokinetics and pharmacodynamics. J Clin Psychiatry 64(Suppl 16): 18-23. (Pubitemid 37523324)
15. Fleischhacker WW, Eerdekens M, Karcher K, et al. 2003. Treatment of schizophrenia with long-acting injectable risperidone: a 12-month open-label trial of the first long-acting second-generation antipsychotic. J Clin Psychiatry 64: 1250-1257.
16. Fleischhacker WW, Rabinowitz J, Kemmler G, Eerdekens M, Mehnert A. 2005. Perceived functioning, well-being and psychiatric symptoms in patients with stable schizophrenia treated with long-acting risperidone for 1 year. Br J Psychiatry 187: 131-136. (Pubitemid 41139684)
17. Geddes J, Freemantle N, Harrison P, Bebbington P. 2000. Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. Br Med J 321: 1371-1376.
18. Guy W. 1976. ECDEU Assessment manual for psychopharmacology. Revised. Rockville, Maryland, USA: US Department of Health, Education and Welfare, 217-222.
19. Harrison TS, Goa KL. 2004. Long-acting risperidone: a review of its use in schizophrenia. CNS Drugs 18: 113-132. (Pubitemid 38293596)
20. Hawley C, Turner M, Latif MA, Curtis V, Saleem PT, Medori R. 2010. Switching stable patients with schizophrenia from depot and oral antipsychotics to long-acting injectable risperidone: reasons for switching and safety. Hum Psychopharmacol 25: 37-46.
21. Jenkinson C, Stewart-Brown S, Petersen S, Paice C. 1999. Assessment of the SF-36 version 2 in the United Kingdom. J Epidemiol Community Health 53: 46-50. (Pubitemid 29012351)
22. Kane JM. 1999. Pharmacologic treatment of schizophrenia. Biol Psychiatry 46: 1396-1408.
23. Kane JM, Eerdekens M, Lindenmayer J-P, Keith SJ, Lesem M, Karcher K. 2003. Long acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic. Am J Psychiatry 160: 1125-1132. (Pubitemid 41070972)
24. Kay SR, Fiszbein A, Opler LA. 1987. The positive and negative syndrome scale for schizophrenia. Schizophrenia Bull 13: 261-276. (Pubitemid 18039085)
25. Keith SJ, Kane JM. 2003. Partial compliance and patient consequences in schizophrenia: our patients can do better. J Clin Psychiatry 64: 1308-1315.
26. Keith SJ, Kane JM, Turner M, Conley RR, Nasrallah HA. 2004. Academic highlights: guidelines for the use of long-acting injectable atypical antipsychotics. J Clin Psychiatry 65: 120-131.
27. Knox ED, Stimmel GL. 2004. Clinical review of a long-acting, injectable formulation of risperidone. Clin Therapeut 26: 1194-2002.
28. Leal A, Rosillon D, Mehnert A, Jarema M, Remington G. 2004. Healthcare resource utilisation during one year treatment with long-acting, injectable risperidone. Pharmacoepidemiol Drug Saf 13: 811-816. (Pubitemid 39496905)
29. Leucht S, Pitschel-Walz G, Abraham D, Kissling W. 1999. Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo: a letter analysis of randomised controlled trials. Schizophrenia Res 35: 51-68. (Pubitemid 29023554)
30. Lieberman JA, Stroup TS, McEvoy JP, et al. 2005. Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. New Engl J Med 353: 1209-1223.
31. Lindenmayer JP, Eerdekens E, Berry SA, Eerdekens M. 2004. Safety and efficacy of long-acting risperidone in schizophrenia: a 12-week, multicentre, open-label study in stable patients switched from typical and atypical oral antipsychotics. J Clin Psychiatry 65: 1084-1089.
32. Llorca PM, Sacchetti E, Lloyd K, Kissling W, Medori R. 2008. Long-term remission in schizophrenia and related psychoses with long-acting risperidone: results obtained in an open-label study with an observation period of 18 months. Int J Clin Pharmacol Ther 46: 14-22.
33. Marder SR, Davis JM, Chouinard G. 1997. The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials. J Clin Psychiatry 58: 538-546. (Pubitemid 28100274)
34. Marowitz JS, Brown CS, Moore TR. 1999. Atypical antipsychotics, Part I: pharmacology pharmacokinetics, and efficacy. Annal Pharmacother 33: 73-83.
35. Möller HJ. 2005. Antipsychotic agents. Gradually improving treatment from the traditional oral neuroleptics to the first atypical depot. Eur Psychiarty 20: 379-385.
36. Möller HJ, Llorca PM, Sacchetti E, et al. 2005. Efficacy and safety of direct transition to risperidone long-acting injectable in patients treated with various antipsychotic therapies. Intl Clin Psychopharmacol 20: 121-130. (Pubitemid 40571509)
37. Niaz OS, Haddad PM. 2007. Thirty-five months experience of risperidone long-acting injection in a UK psychiatric service including a mirror-image analysis of in-patient care. Acta Psychiatr Scand 116: 36-46.
38. Nasrallah HA, Duchesne I, Mehnert A, Janagap C, Eerdekens M. 2004. Health-related quality of life in patients with schizophrenia during treatment with long acting, injectable risperidone. J Clin Psychiatry 65: 531-535.
39. 2003National Institute for [Health and] Clinical Excellence. 2003. Schizophrenia. Full National Clinical Guideline on Core Interventions in Primary and Secondary Care. Royal College of Psychiatrists: London.
40. Taylor DM, Young CL, Mace S, Patel MX. 2004. Early clinical experience with risperidone long-acting injection: a prospective, 6-month follow-up of 100 patients. J Clin Psychiatry 65: 1076-1083.
41. Tunis SL, Croghan TW, Heilman DK, Johnstone BM, Obenchain RT. 1999. Reliability, validity, and application of the medical outcomes study 36-item short-form health survey (SF-36) in schizophrenic patients treated with olanzapine versus haloperidol. Med Care 37: 678-691.
42. Valenstein M, Blow FC, Copeland LA, et al. 2004. Poor antipsychotic adherence among patients with schizophrenia: medication and patient factors. Schizophrenia Bull 30: 255-264. (Pubitemid 38828533)
43. Ware J, Snow K, Kosinski M. 1993. SF-36 Health Survey Manual and Interpretation Guide. Boston, Massachusetts. The Health Institute.
44. Weiden PJ, Kozma C, Grogg A, Locklear J. 2004. Partial compliance and risk of rehospitalization among California Medicaid patients with schizophrenia. Psychiat Serv 55: 886-891. (Pubitemid 39025215)
45. Weiden J, Zygmunt A. 1997. Medication noncompliance in Schizophrenia, Pt 1: assessment. J Pract Psychiatry Behav Healt: 106-111.
46. Young CL, Taylor DM. 2006. Health resource utilization associated with switching to risperidone long-acting injection. Acta Psychiatr Scand 114: 14-20. (Pubitemid 43885480)